Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D3.333 - Unveiling the Role of PGD2/CRTH2 Signaling in Antigen-Specific IgE Production
D3.334 - Characterization of novel nickel specific cd4+ regulatory T cells from a nickel sensitized joint implant failure patient
D3.335 - The role of activated leukocyte cell-adhesion molecule in hyperoxia induced acute lung injury
D3.336 - CC variant of the -634G/C polymorphism of the VEGF gene is associated with higher HDL levels in patients with type 1 diabetes mellitus
D3.337 - The -634G/C polymorphism of the VEGF gene affects BPI concentration in patients with type 1 diabetes mellitus
D3.338 - The sCD14 level in patients with type 1 diabetes mellitus may be related to the -786T/C polymorphism of the NOS3 gene
D3.339 - Assessment of the immune status of systemic sclerosis patients by flow cytometry
D3.340 - Protocol for autofluorescence-driven isolation of human peripheral blood eosinophils
D3.342 - Involvement of periostin-dependent and -independent pathways in the formation of skin inflammation and itch in a mouse model of atopic dermatitis
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
D3.418 - Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists
D3.420 - IL-1β, IL-6, and TNF serum levels in mastocytosis are not correlated with psychometric measures, though they correlate to serum tryptase and recurrent edemas
D3.422 - Evaluating Elevated Baseline Mast Cell Tryptase: Insights from an Adult Allergy Service
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download